{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Insulin+aspart",
    "query": {
      "intervention": "Insulin aspart"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 180,
    "total_pages": 18,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Insulin+aspart&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-04T00:14:36.811Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02328040",
      "title": "Randomized Trial Comparing Sitagliptin to Placebo in Closed Loop",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Diabetes Mellitus, Type 1"
      ],
      "interventions": [
        {
          "name": "Placebo and Insulin monotherapy via CL",
          "type": "DRUG"
        },
        {
          "name": "Sitagliptin and insulin/novolog via CL",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Albert Einstein College of Medicine",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "14 Years",
        "maximum_age": "30 Years",
        "sex": "ALL",
        "summary": "14 Years to 30 Years"
      },
      "enrollment_count": 17,
      "start_date": "2014-09",
      "completion_date": "2016-01",
      "has_results": true,
      "last_update_posted_date": "2018-08-07",
      "last_synced_at": "2026-09-04T00:14:36.811Z",
      "location_count": 1,
      "location_summary": "The Bronx, New York",
      "locations": [
        {
          "city": "The Bronx",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02328040"
    },
    {
      "nct_id": "NCT05184868",
      "title": "AT247, NovoLog® and Fiasp® Administered Via Continuous Subcutaneous Infusion in Glucose Clamp Study",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Diabetes Mellitus, Type 1"
      ],
      "interventions": [
        {
          "name": "AT247",
          "type": "DRUG"
        },
        {
          "name": "NovoLog",
          "type": "DRUG"
        },
        {
          "name": "Fiasp",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Arecor Limited",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 24,
      "start_date": "2022-01-03",
      "completion_date": "2022-09-09",
      "has_results": false,
      "last_update_posted_date": "2022-09-13",
      "last_synced_at": "2026-09-04T00:14:36.811Z",
      "location_count": 1,
      "location_summary": "Chula Vista, California",
      "locations": [
        {
          "city": "Chula Vista",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05184868"
    },
    {
      "nct_id": "NCT04460326",
      "title": "Novolog vs. Fiasp Insulin in Non-critically Ill Hospitalized Patients With Type 2 Diabetes Mellitus",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Type 2 Diabetes Treated With Insulin"
      ],
      "interventions": [
        {
          "name": "Insulin glargine",
          "type": "DRUG"
        },
        {
          "name": "NovoLog",
          "type": "DRUG"
        },
        {
          "name": "Insulin Fiasp",
          "type": "DRUG"
        },
        {
          "name": "Standard carbohydrate diet",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Boston Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "21 Years to 80 Years"
      },
      "enrollment_count": 137,
      "start_date": "2020-12-07",
      "completion_date": "2023-05-27",
      "has_results": true,
      "last_update_posted_date": "2024-03-19",
      "last_synced_at": "2026-09-04T00:14:36.811Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04460326"
    },
    {
      "nct_id": "NCT00442767",
      "title": "Post-meal Insulin Dosing With Adjuvant Pre-meal Pramlintide in Children With Type 1 Diabetes Mellitus",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Type 1 Diabetes Mellitus"
      ],
      "interventions": [
        {
          "name": "Insulin",
          "type": "DRUG"
        },
        {
          "name": "Pramlintide + Insulin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Montefiore Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": "21 Years",
        "sex": "ALL",
        "summary": "12 Years to 21 Years"
      },
      "enrollment_count": 8,
      "start_date": "2007-02",
      "completion_date": "2009-02",
      "has_results": true,
      "last_update_posted_date": "2018-07-10",
      "last_synced_at": "2026-09-04T00:14:36.811Z",
      "location_count": 1,
      "location_summary": "The Bronx, New York",
      "locations": [
        {
          "city": "The Bronx",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00442767"
    },
    {
      "nct_id": "NCT00322257",
      "title": "Safety and Efficacy of Inhaled Insulin in Type 1 Diabetes",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Diabetes",
        "Diabetes Mellitus, Type 1"
      ],
      "interventions": [
        {
          "name": "inhaled human insulin",
          "type": "DRUG"
        },
        {
          "name": "insulin detemir",
          "type": "DRUG"
        },
        {
          "name": "insulin aspart",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novo Nordisk A/S",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 596,
      "start_date": "2006-05-01",
      "completion_date": "2008-04-02",
      "has_results": false,
      "last_update_posted_date": "2018-09-05",
      "last_synced_at": "2026-09-04T00:14:36.811Z",
      "location_count": 86,
      "location_summary": "Birmingham, Alabama • Tuscaloosa, Alabama • Concord, California + 78 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Tuscaloosa",
          "state": "Alabama"
        },
        {
          "city": "Concord",
          "state": "California"
        },
        {
          "city": "Encino",
          "state": "California"
        },
        {
          "city": "Escondido",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00322257"
    },
    {
      "nct_id": "NCT01165684",
      "title": "Efficacy and Safety of Basal-bolus Therapy, Comparing Stepwise Addition of Insulin Aspart Versus Complete Basal-bolus Regimen",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Diabetes",
        "Diabetes Mellitus, Type 2"
      ],
      "interventions": [
        {
          "name": "insulin aspart",
          "type": "DRUG"
        },
        {
          "name": "insulin detemir",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novo Nordisk A/S",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 401,
      "start_date": "2010-10",
      "completion_date": "2012-04",
      "has_results": true,
      "last_update_posted_date": "2017-02-17",
      "last_synced_at": "2026-09-04T00:14:36.811Z",
      "location_count": 33,
      "location_summary": "Birmingham, Alabama • Mesa, Arizona • Scottsdale, Arizona + 28 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Mesa",
          "state": "Arizona"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Fresno",
          "state": "California"
        },
        {
          "city": "Hialeah",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01165684"
    },
    {
      "nct_id": "NCT04409587",
      "title": "Basal Insulin Glycemic ControL With DEglugec vs Aspart Via Pump",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Type1 Diabetes Mellitus"
      ],
      "interventions": [
        {
          "name": "Aspart",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Mountain Diabetes and Endocrine Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 59,
      "start_date": "2018-04-12",
      "completion_date": "2020-11-01",
      "has_results": false,
      "last_update_posted_date": "2021-02-24",
      "last_synced_at": "2026-09-04T00:14:36.811Z",
      "location_count": 1,
      "location_summary": "Asheville, North Carolina",
      "locations": [
        {
          "city": "Asheville",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04409587"
    },
    {
      "nct_id": "NCT00523042",
      "title": "Safety of Inhaled Preprandial Human Insulin in Subjects With Diabetes and Asthma",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Diabetes",
        "Diabetes Mellitus, Type 1",
        "Diabetes Mellitus, Type 2",
        "Asthma"
      ],
      "interventions": [
        {
          "name": "insulin aspart",
          "type": "DRUG"
        },
        {
          "name": "inhaled human insulin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novo Nordisk A/S",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 10,
      "start_date": "2007-08-30",
      "completion_date": "2008-02-28",
      "has_results": false,
      "last_update_posted_date": "2018-09-05",
      "last_synced_at": "2026-09-04T00:14:36.811Z",
      "location_count": 9,
      "location_summary": "Fresno, California • New Orleans, Louisiana • Kansas City, Missouri + 6 more",
      "locations": [
        {
          "city": "Fresno",
          "state": "California"
        },
        {
          "city": "New Orleans",
          "state": "Louisiana"
        },
        {
          "city": "Kansas City",
          "state": "Missouri"
        },
        {
          "city": "Columbus",
          "state": "Ohio"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00523042"
    },
    {
      "nct_id": "NCT01275131",
      "title": "Randomized, Double-blind, Crossover, Pharmacokinetic (PK) and Glucodynamic (GD) Study of Continuous Subcutaneous Insulin Infusion (CSII) in Participants With Type 1 Diabetes Mellitus (T1DM)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Type 1 Diabetes Mellitus"
      ],
      "interventions": [
        {
          "name": "Insulin aspart",
          "type": "DRUG"
        },
        {
          "name": "Recombinant human hyaluronidase PH20 (rHuPH20)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Halozyme Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 45,
      "start_date": "2011-01",
      "completion_date": "2011-12",
      "has_results": true,
      "last_update_posted_date": "2014-07-25",
      "last_synced_at": "2026-09-04T00:14:36.811Z",
      "location_count": 1,
      "location_summary": "Chula Vista, California",
      "locations": [
        {
          "city": "Chula Vista",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01275131"
    },
    {
      "nct_id": "NCT04538352",
      "title": "Transition From Basal/Bolus to Once-weekly Subcutaneous Semaglutide and Basal Insulin in Patients With T2D",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Type 2 Diabetes"
      ],
      "interventions": [
        {
          "name": "Semaglutide",
          "type": "DRUG"
        },
        {
          "name": "Insulin Degludec",
          "type": "DRUG"
        },
        {
          "name": "Insulin aspart",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "The Cleveland Clinic",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 60,
      "start_date": "2021-01-18",
      "completion_date": "2023-11-01",
      "has_results": true,
      "last_update_posted_date": "2025-02-18",
      "last_synced_at": "2026-09-04T00:14:36.811Z",
      "location_count": 1,
      "location_summary": "Cleveland, Ohio",
      "locations": [
        {
          "city": "Cleveland",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04538352"
    }
  ]
}